{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-102293","form_type":"8-K","ticker":"ELOX","cik":"0001035354","company_name":"Eloxx Pharmaceuticals, Inc.","filed_at":"2023-09-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:32.945540+00:00","generated_at":"2026-06-10T11:42:16.933961+00:00","sec_items":["1.01","3.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Eloxx Pharmaceuticals raises ~$2M in registered direct offering and private placement","bullets":["Sold 305,590 shares + 75,000 pre-funded warrants at ~$5.255/unit, and 380,590 private warrants at $5.13 exercise.","Gross proceeds approximately $2.0M; H.C. Wainwright placement agent with 7.5% fee and 22,835 warrant shares.","Private and placement warrants issued unregistered under Section 4(a)(2) exemption.","Pre-funded warrant exercise price $0.001; private warrant term 5.5 years; both have beneficial ownership caps.","Proceeds intended for general corporate purposes."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-102293","json":"https://secwatch.observer/filing/0001104659-23-102293.json","markdown":"https://secwatch.observer/filing/0001104659-23-102293.md","text":"https://secwatch.observer/filing/0001104659-23-102293.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1035354/000110465923102293/0001104659-23-102293-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1035354/000110465923102293/tm2326470d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T11:42:16.933961+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8ad768afd9e4ae7647ad05beb0be6e36b38138cd","claim":"Eloxx Pharmaceuticals, Inc. entered into Purchase Agreement with a certain institutional investor (effective 2023-09-18).","evidence_excerpt":"On September 18, 2023, Eloxx Pharmaceuticals, Inc., a Delaware corporation (the “Company”), entered into a securities purchase agreement (the “Purchase Agreement”) with a certain institutional investor (the “Purchaser”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1035354/000110465923102293/0001104659-23-102293-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"a certain institutional investor"},{"label":"Effective","value":"2023-09-18"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}